Hydroxychloroquine, a drug used to prevent malaria and treat certain autoimmune conditions, is being studied to treat or prevent COVID-19
The findings suggested hydroxychloroquine did not benefit patients and A study of nearly 1,400 patients with moderate to severe COVID-19 disease at a single New York hospital found that patients who received the drug fared no better than patients who did not receive the drug
Boulware et al
The study said hydroxychloroquine “did not significantly improve clinical status at day 14″ among hospitalized patients with respiratory illness from COVID-19
An association of increased overall mortality was identified in patients treated with
It is also used to prevent malaria infection in areas or regions where there is no known medicine (eg, chloroquine) resistance
Results: Alopecia scores of five patients improved by 6 months of treatment
1k
In ending the hydroxychloroquine study, Henry Ford said it was shifting its focus to vaccines as the “primary strategy of protecting our frontline workers,” according to an emailed statement to Bridge Michigan attributed to Dr
A recent study has identified these two compounds (azithromycin and hydroxychloroquine) among 97 total potentially active agents as possible treatments for this disease